|
GlaxoSmithKline’s approach to developing a semi-continuous manufacturing platform is to maximize equipment utilization and reduce the capital investment required for future facilities, resulting in a flexible and small manufacturing platform that can support varying BDS manufacturing demands.
Speaker:
Mehdi Ghodbane, PhD,Scientific Leader, Biopharmaceutical Product Development & Supply, GlaxoSmithKline
|